Chickpea (Cicer arietinum L.) production in the Northern Great Plains is limited by very few broadleaf weed control options. Field experiments were conducted at two locations in 2012 and at three locations in 2013 in Saskatchewan, Canada, to examine the performance of the conventional and the imidazolinone (IMI) resistant chickpea cultivars to post-emergence application of imazamox or imazethapyr applied alone or in tank-mix. Treatments included imazamox (20 and 40 g a.i. ha-1), imazethapyr (50 and 100 g a.i. ha-1), and a tank-mixture of imazamox (35%) imazethapyr (35%) (30 and 60 g a.i. ha-1). Conventional cultivars, CDC Luna and CDC Corinne, showed moderate to severe injury compared with resistant cultivars, CDC Alma and CDC Cory, which showed minimal to no injury. Plant height was arrested and node development slowed for conventional cultivars treated with IMI herbicides. This susceptibility to IMI herbicides was also noted with a delay in flowering and maturity. Despite a significant negative response, CDC Luna and CDC Corinne were able to recover throughout the growing season resulting in no yield loss from IMI treatments at all locations, except one. Resistant cultivars, CDC Alma and CDC Cory, demonstrated no significant injury from IMI herbicide compared with the untreated controls. These results show the potential to use IMI herbicides in the resistant chickpea cultivars, expanding the currently limited options for broadleaf weed control in chickpea cultivation.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.